Amiloride-sensitive sodium channel subunit beta (SCNN1B) (SCNN1B)

The Amiloride-sensitive sodium channel subunit beta (SCNN1B) is a fundamental component of the heterotrimeric epithelial sodium channel (ENaC) complex, which mediates the rate-limiting step of sodium reabsorption across the apical membranes of epithelial cells (UniProt P51168). Primarily expressed in the distal nephron, colon, and respiratory tract, this subunit is essential for maintaining total body salt and water homeostasis, thereby playing a critical role in the regulation of blood pressure and airway surface liquid volume (PubMed 29038247). Mutations in the SCNN1B gene are linked to significant clinical disorders; gain-of-function mutations cause Liddle syndrome, a form of hereditary hypertension, while loss-of-function mutations lead to Pseudohypoaldosteronism type 1, characterized by severe salt wasting (StatPearls NBK562150). Pharmacologically, the ENaC complex is the primary target for potassium-sparing diuretics such as amiloride and triamterene, which block the channel pore to inhibit sodium uptake (PubChem CID 2162). Beyond renal applications, the beta subunit is a target of interest in treating cystic fibrosis and other obstructive lung diseases, where inhibiting ENaC can help restore airway hydration and improve mucociliary clearance (PubMed 31431415). Consequently, the beta subunit is a vital therapeutic target for managing both cardiovascular and respiratory conditions.

Other names

Epithelial sodium channel subunit betaBeta-ENaCNon-voltage-gated sodium channel 1 subunit betaSCNNBENaCbSCNEB

Direct inhibition of the epithelial sodium channel (ENaC) complex, preventing the entry of sodium ions into epithelial cells from the lumen, which leads to decreased sodium reabsorption and increased water retention in the lumen (PubChem CID 2162).